Aspire Biopharma Holdings, Inc. (ASBP) vs Bluejay Diagnostics, Inc. (BJDX)
A side-by-side comparison of Aspire Biopharma Holdings, Inc. and Bluejay Diagnostics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ASBP
Aspire Biopharma Holdings, Inc.
$8.95HealthcareDelayed quote: Oct 6, 2026, 3:31 PM EDT
BJDX
Bluejay Diagnostics, Inc.
$0.81HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — ASBP vs BJDX
growth of $100 · dividends reinvested · last 4yASBP -99.9% (-83.5%/yr)BJDX -100.0% (-93.2%/yr)ASBP compounded faster over this window
Log scale — wide-divergence pair
ASBP BJDX
ASBP vs BJDX: by the numbers
- •ASBP is the larger company ($1M vs $836773 market cap).
- •Both run net losses; BJDX's is the smaller (0.00% vs -11314.24% net margin).
Metrics side by side
Valuation
| Metric | ASBP | BJDX |
|---|---|---|
| P/S ratio | 10.57 | N/A |
| P/B ratio | 0.09 | 0.09 |
Profitability
| Metric | ASBP | BJDX |
|---|---|---|
| Gross margin | -1.87% | 0.00% |
| Operating margin | -312016.95% | 0.00% |
| Net margin | -11314.24% | 0.00% |
| ROE | -93.97% | -77.23% |
| ROIC | -59.81% | -77.55% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.